Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Drug interactions with cannabinoids

Tony Antoniou, Jack Bodkin and Joanne M.-W. Ho
CMAJ March 02, 2020 192 (9) E206; DOI: https://doi.org/10.1503/cmaj.191097
Tony Antoniou
Department of Family and Community Medicine (Antoniou), St. Michael’s Hospital and University of Toronto; Li Ka Shing Knowledge Institute (Antoniou), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Bodkin, Ho), McMaster University, Waterloo, Ont.; Grand River Hospital (Bodkin), Kitchener, Ont.; Schlegel Research Institute for Aging (Ho), Waterloo, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Bodkin
Department of Family and Community Medicine (Antoniou), St. Michael’s Hospital and University of Toronto; Li Ka Shing Knowledge Institute (Antoniou), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Bodkin, Ho), McMaster University, Waterloo, Ont.; Grand River Hospital (Bodkin), Kitchener, Ont.; Schlegel Research Institute for Aging (Ho), Waterloo, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne M.-W. Ho
Department of Family and Community Medicine (Antoniou), St. Michael’s Hospital and University of Toronto; Li Ka Shing Knowledge Institute (Antoniou), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Bodkin, Ho), McMaster University, Waterloo, Ont.; Grand River Hospital (Bodkin), Kitchener, Ont.; Schlegel Research Institute for Aging (Ho), Waterloo, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Cannabinoid levels can be increased by other medications

Delta-9-tetrahydrocannabinol (THC) and cannabidiol are pharmacologically active cannabinoids in marijuana that are metabolized by cytochrome P450 (CYP)3A4; THC is also metabolized by CYP2C9, a liver enzyme.1 A pharmacokinetic study found that the CYP3A4 inhibitor ketoconazole nearly doubled THC and cannabidiol concentrations,2 and similar interactions could occur with other CYP3A4 inhibitors, including macrolides and verapamil, augmenting the psychoactive effects of THC and dose-related adverse effects of cannabidiol (e.g., somnolence, transaminase elevation).1,2 CYP2C9 inhibitors such as cotrimoxazole, fluoxetine and amiodarone would also be expected to increase THC exposure and psychoactive effects.1

Cannabinoids can affect levels of other drugs

Cannabidiol inhibits CYP2C19, increasing levels of the active metabolite of clobazam threefold.1,3 Interactions with other drugs metabolized by CYP2C19 (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.191097/-/DC1) should be anticipated. Very high international normalized ratio levels and bleeding have been reported with combined used of warfarin and marijuana.1 A case reporting a threefold increase in tacrolimus levels following the addition of cannabidiol shows that CYP3A4/5 inhibition can also occur.4

Smoking marijuana can increase clearance of some drugs

Smoked marijuana increases the clearance of theophylline 40%.1 Similar findings would be expected for other drugs metabolized by CYP1A2, such as olanzapine. Increased drug clearance occurs with regular marijuana use (> 2 marijuana cigarettes per week); no effect of occasional use has been reported.

Additive effects can occur with other drugs

Additive effects can occur when marijuana is combined with sympathomimetics (e.g., tachycardia, hypertension), central nervous system depressants such as alcohol and opioids (e.g., drowsiness, ataxia), and anticholinergics (e.g., tachycardia, confusion).5

There are potential “red flag” interactions

Though further research is needed, marijuana may have serious interactions with drugs including warfarin (increased international normalized ratio and risk of bleeding); clobazam (increased risk of benzodiazepine toxicity); central nervous sytem depressants and sympathomimetics (additive effects); and theophylline, clozapine and olanzapine (reduced efficacy). Patients should be advised about possible increased cannabinoid effects with concomitant CYP3A4 and 2C9 inhibitors (Appendix 1).1,5 Alternatives that do not interact with marijuana should be selected when clinically feasible.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Cox EJ,
    2. Maharao N,
    3. Patilea-Vrana G,
    4. et al
    . A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics. Pharmacol Ther 2019;201:25–38.
    OpenUrl
  2. ↵
    1. Stott C,
    2. White L,
    3. Wright S,
    4. et al
    . A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus 2013;2:236.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Geffrey AL,
    2. Pollack SF,
    3. Bruno PL,
    4. et al
    . Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015;56:1246–51.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Leino AD,
    2. Emoto C,
    3. Fukuda T,
    4. et al
    . Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant 2019;19:2944–8.
    OpenUrl
  5. ↵
    1. Lucas CJ,
    2. Galettis P,
    3. Schneider J
    . The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018;84:2477–82.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (9)
CMAJ
Vol. 192, Issue 9
2 Mar 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drug interactions with cannabinoids
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drug interactions with cannabinoids
Tony Antoniou, Jack Bodkin, Joanne M.-W. Ho
CMAJ Mar 2020, 192 (9) E206; DOI: 10.1503/cmaj.191097

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Drug interactions with cannabinoids
Tony Antoniou, Jack Bodkin, Joanne M.-W. Ho
CMAJ Mar 2020, 192 (9) E206; DOI: 10.1503/cmaj.191097
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Cannabinoid levels can be increased by other medications
    • Cannabinoids can affect levels of other drugs
    • Smoking marijuana can increase clearance of some drugs
    • Additive effects can occur with other drugs
    • There are potential “red flag” interactions
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Attitudes toward medical cannabis among family physicians practising in Ontario, Canada: a qualitative research study
  • Google Scholar

More in this TOC Section

  • Duodenal duplication cyst in a 61-year-old man
  • A young woman with fever and polyserositis caused by familial Mediterranean fever
  • Screening for primary aldosteronism in primary care
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Cannabis
    • Drugs: adverse reactions
    • Family medicine, general practice, primary care
    • Internal medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire